Colonization by B. infantis EVC001 modulates enteric inflammation in exclusively breastfed infants
Bethany M Henrick, Stephanie Chew, Giorgio Casaburi, Heather K Brown, Steven A Frese, You Zhou, Mark A Underwood, Jennifer T Smilowitz, Bethany M Henrick, Stephanie Chew, Giorgio Casaburi, Heather K Brown, Steven A Frese, You Zhou, Mark A Underwood, Jennifer T Smilowitz
Abstract
Background: Infant gut dysbiosis, often associated with low abundance of bifidobacteria, is linked to impaired immune development and inflammation-a risk factor for increased incidence of several childhood diseases. We investigated the impact of B. infantis EVC001 colonization on enteric inflammation in a subset of exclusively breastfed term infants from a larger clinical study.
Methods: Stool samples (n = 120) were collected from infants randomly selected to receive either 1.8 × 1010 CFU B. infantis EVC001 daily for 21 days (EVC001) or breast milk alone (controls), starting at day 7 postnatal. The fecal microbiome was analyzed using 16S ribosomal RNA, proinflammatory cytokines using multiplexed immunoassay, and fecal calprotectin using ELISA at three time points: days 6 (Baseline), 40, and 60 postnatal.
Results: Fecal calprotectin concentration negatively correlated with Bifidobacterium abundance (P < 0.0001; ρ = -0.72), and proinflammatory cytokines correlated with Clostridiaceae and Enterobacteriaceae, yet negatively correlated with Bifidobacteriaceae abundance. Proinflammatory cytokines were significantly lower in EVC001-fed infants on days 40 and 60 postnatally compared to baseline and compared to control infants.
Conclusion: Our findings indicate that gut dysbiosis (absence of B. infantis) is associated with increased intestinal inflammation. Early addition of EVC001 to diet represents a novel strategy to prevent enteric inflammation during a critical developmental phase.
Conflict of interest statement
B.M.H., S.C., G.C., H.K.B., and S.A.F. are employees of Evolve Biosystems, a company focused on restoring the infant microbiome. J.T.S. previously worked as a consultant for Evolve Biosystems. The other authors declare no competing interests.
Figures
References
- Olin A, et al. Stereotypic immune system development in newborn children. Cell. 2018;174:1277–1292. doi: 10.1016/j.cell.2018.06.045.
- Arrieta M-C, et al. Associations between infant fungal and bacterial dysbiosis and childhood atopic wheeze in a nonindustrialized setting. J. Allergy Clin. Immunol. 2018;142:424–434. doi: 10.1016/j.jaci.2017.08.041.
- Arrieta M-C, et al. Early infancy microbial and metabolic alterations affect risk of childhood asthma. Sci. Transl. Med. 2015;7:307ra152-2. doi: 10.1126/scitranslmed.aab2271.
- Rhoads JM, et al. Infant colic represents gut inflammation and dysbiosis. J. Pediatr. 2018;203:55–61. doi: 10.1016/j.jpeds.2018.07.042.
- Fujimura KE, et al. Neonatal gut microbiota associates with childhood multisensitized atopy and T cell differentiation. Nat. Med. 2016;22:1187–1191. doi: 10.1038/nm.4176.
- Kostic AD, et al. The dynamics of the human infant gut microbiome in development and in progression toward type 1 diabetes. Cell Host Microbe. 2015;17:260–273. doi: 10.1016/j.chom.2015.01.001.
- Vatanen T, et al. Variation in microbiome LPS immunogenicity contributes to autoimmunity in humans. Cell. 2016;165:1–12. doi: 10.1016/j.cell.2016.05.056.
- Cox LM, et al. Altering the intestinal microbiota during a critical developmental window has lasting metabolic consequences. Cell. 2014;158:705–721. doi: 10.1016/j.cell.2014.05.052.
- Gevers D, et al. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe. 2014;15:382–392. doi: 10.1016/j.chom.2014.02.005.
- Russell SL, et al. Perinatal antibiotic treatment affects murine microbiota, immune responses and allergic asthma. Gut Microbes. 2013;4:158–164. doi: 10.4161/gmic.23567.
- Cahenzli J, et al. Intestinal Microbial diversity during early-life colonization shapes long-term IgE levels. Cell Host Microbe. 2013;14:559–570. doi: 10.1016/j.chom.2013.10.004.
- Ho TTB, et al. Enteric dysbiosis and fecal calprotectin expression in premature infants. Pediatr. Res. 2019;85:361–368. doi: 10.1038/s41390-018-0254-y.
- Herrera OR, Christensen ML, Helms RA. Calprotectin: clinical applications in pediatrics. J. Pediatr. Pharm. Ther. 2016;21:308–321.
- Nakayuenyongsuk W, et al. Point-of-care fecal calprotectin monitoring in preterm infants at risk for necrotizing enterocolitis. J. Pediatr. 2018;196:98–103. doi: 10.1016/j.jpeds.2017.12.069.
- Campeotto F, et al. Fecal calprotectin: cutoff values for identifying intestinal distress in preterm infants. J. Pediatr. Gastroenterol. Nutr. 2009;48:507–510.
- Kapel N, et al. Faecal calprotectin in term and preterm neonates. J. Pediatr. Gastroenterol. Nutr. 2010;51:542–547. doi: 10.1097/MPG.0b013e3181e2ad72.
- Souwer Y, et al. IL-17 and IL-22 in atopic allergic disease. Curr. Opin. Immunol. 2010;22:821–826. doi: 10.1016/j.coi.2010.10.013.
- Liwen Z, et al. A low abundance of Bifidobacterium but not Lactobacillius in the feces of Chinese children with wheezing diseases. Medicine. 2018;97:e12745–e12746. doi: 10.1097/MD.0000000000012745.
- Sjögren YM, et al. Altered early infant gut microbiota in children developing allergy up to 5 years of age. Clin. Exp. Allergy. 2009;39:518–526. doi: 10.1111/j.1365-2222.2008.03156.x.
- Rizzetto L, et al. Connecting the immune system, systemic chronic inflammation and the gut microbiome: the role of sex. J. Autoimmun. 2018;92:12–34. doi: 10.1016/j.jaut.2018.05.008.
- Zhang Y, et al. Variations in early gut microbiome are associated with childhood eczema. FEMS Microbiol. Lett. 2019;366:fnz020. doi: 10.1093/femsle/fnz020.
- Maffeis C, et al. Association between intestinal permeability and faecal microbiota composition in Italian children with beta cell autoimmunity at risk for type 1 diabetes. Diabetes Metab. Res. Rev. 2016;32:700–709. doi: 10.1002/dmrr.2790.
- Hollander D. Crohn’s disease-a permeability disorder of the tight junction? Gut. 1988;29:1621–1624. doi: 10.1136/gut.29.12.1621.
- Al-Sadi R, Boivin M, Ma T. Mechanism of cytokine modulation of epithelial tight junction barrier. Front. Biosci. (Landmark Ed.) 2009;14:2765–2778. doi: 10.2741/3413.
- Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. Science. 2012;336:1268–1273. doi: 10.1126/science.1223490.
- Shin N-R, Whon TW, Bae J-W. Proteobacteria: microbial signature of dysbiosis in gut microbiota. Trends Biotechnol. 2015;33:496–503. doi: 10.1016/j.tibtech.2015.06.011.
- Frese SA, et al. Persistence of supplemented Bifidobacterium longum subsp. infantis EVC001 in breastfed infants. mSphere. 2017;2:e00501-17. doi: 10.1128/mSphere.00501-17.
- Huda MN, et al. Bifidobacterium abundance in early infancy and vaccine response at 2 years of age. Pediatrics. 2019;143:e20181489. doi: 10.1542/peds.2018-1489.
- Sela DA, et al. The genome sequence of Bifidobacterium longum subsp. infantis reveals adaptations for milk utilization within the infant microbiome. Proc. Natl Acad. Sci. 2008;105:18964–18969. doi: 10.1073/pnas.0809584105.
- Henrick BM, et al. Elevated fecal pH indicates a profound change in the breastfed infant gut microbiome due to reduction of Bifidobacterium over the past century. mSphere. 2018;3:e00041-18. doi: 10.1128/mSphere.00041-18.
- Karav S, Casaburi G, Frese SA. Reduced colonic mucin degradation in breastfed infants colonized by Bifidobacterium longum subsp. infantis EVC001. FEBS Open Bio. 2018;8:1649–1657. doi: 10.1002/2211-5463.12516.
- Smilowitz JT, et al. Safety and tolerability of Bifidobacterium longum subspecies infantis EVC001 supplementation in healthy term breastfed infants: a phase I clinical trial. BMC Pediatr. 2017;17:1–11. doi: 10.1186/s12887-016-0759-7.
- Houser MC, et al. Stool immune profiles evince gastrointestinal inflammation in Parkinson’s disease. Mov. Disord. 2018;33:793–804. doi: 10.1002/mds.27326.
- Vázquez-Baeza Y, et al. EMPeror: a tool for visualizing high-throughput microbial community data. Gigascience. 2013;2:16. doi: 10.1186/2047-217X-2-16.
- Zeng MY, Inohara N, Nunez G. Mechanisms of inflammation-driven bacterial dysbiosis in the gut. Mucosal Immunol. 2016;10:18–26. doi: 10.1038/mi.2016.75.
- Orivuori L, et al. High level of fecal calprotectin at age 2 months as a marker of intestinal inflammation predicts atopic dermatitis and asthma by age 6. Clin. Exp. Allergy. 2015;45:928–939. doi: 10.1111/cea.12522.
- Wickramasinghe S, et al. Bifidobacteria grown on human milk oligosaccharides downregulate the expression of inflammation-related genes in Caco-2 cells. BMC Microbiol. 2015;15:172. doi: 10.1186/s12866-015-0508-3.
- Bergmann KR, et al. Bifidobacteria stabilize claudins at tight junctions and prevent intestinal barrier dysfunction in mouse necrotizing enterocolitis. Am. J. Pathol. 2013;182:1595–1606. doi: 10.1016/j.ajpath.2013.01.013.
- Guo S, et al. Secreted metabolites of Bifidobacterium infantis and Lactobacillus acidophilus protect immature human enterocytes from IL-1β-induced inflammation: a transcription profiling analysis. PLoS ONE. 2015;10:e0124549-19.
- Aragozzini F, et al. Indole-3-lactic acid as a tryptophan metabolite produced by Bifidobacterium spp. Appl. Environ. Microbiol. 1979;38:544–546.
- Ehrlich, A. M. et al. Bifidobacterium grown on human milk oligosaccharides produce tryptophan metabolite Indole-3-lactic acid that significantly decreases inflammation in intestinal cells in vitro. FASEB J. 32(1 Suppl), 359 (2018).
Source: PubMed